# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-058642
Filing Date
2024-05-13
Accepted
2024-05-13 16:07:36
Documents
88
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | gyre-20240331.htm iXBRL | 10-Q | 2002851
2 | EX-31.1 | gyre-ex31_1.htm | EX-31.1 | 16295
3 | EX-31.2 | gyre-ex31_2.htm | EX-31.2 | 16289
4 | EX-32.1 | gyre-ex32_1.htm | EX-32.1 | 12283
5 | EX-32.2 | gyre-ex32_2.htm | EX-32.2 | 12277
| Complete submission text file | 0000950170-24-058642.txt |  | 9957494

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | gyre-20240331.xsd | EX-101.SCH | 1483069
92 | EXTRACTED XBRL INSTANCE DOCUMENT | gyre-20240331_htm.xml | XML | 1905148

Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51173 | Film No.: 24939057
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)